Description
Novobismol Pharmacodynamics
Antiulcer with bactericidal activity against Helicobacter pylori. It also has anti-inflammatory and astringent effect. In the acidic environment of the stomach, insoluble bismuth oxychloride and citrate are precipitated; chelated compounds with protein substrate are formed in the form of a protective film on the surface of ulcers and erosions. By increasing the synthesis of prostaglandin E, mucus formation and hydrocarbonate secretion, stimulates the activity of cytoprotective mechanisms, increases the resistance of the gastrointestinal mucosa to pepsin, hydrochloric acid, enzymes and bile acid salts. Leads to the accumulation of epidermal growth factor in the defect area. Reduces the activity of pepsin and pepsinogen.
Indications
– Gastric and duodenal ulcers in the acute phase, including those associated with Helicobacter pylori;
– chronic gastritis and gastroduodenitis in the acute phase, including those associated with Helicobacter pylori;
– Functional dyspepsia, not associated with organic gastrointestinal diseases;
– Irritable bowel syndrome, occurring mainly with symptoms of diarrhea.
Contraindications
– Severe renal dysfunction;
– pregnancy;
– lactation;
– Children under 4 years of age;
– Individual intolerance to the drug.
Dosage and administration method
- Adults and children over 12 years of age are prescribed 1 tablet. Three times a day for 30 minutes before a meal and 1 tablet at night, or 2 tablets. 2 times a day 30 min before a meal.
- Children of 8 to 12 years of age are prescribed 1 tablet. 2 times a day 30 minutes before a meal.
- Children aged 4 to 8 years old are prescribed in a dose of 8 mg/kg/day; the daily dose is divided into 2 doses. It is taken 30 minutes before a meal.
- Tablets should be swallowed with a small amount of water. The course of treatment lasts 4 to 8 weeks. During the next 8 weeks, bismuth-containing drugs should not be used. For eradication of Helicobacter pylori it is advisable to use bismuth tricalium dicitrate in combination with other antibacterial agents having anti-Helicobacter activity.
- Dosing regimen, method of administration and duration of treatment:
- The drug should not be used for more than 8 weeks. During treatment with Novobismol® it is not recommended to exceed the established daily doses for adults and children.
- Do not use other drugs containing bismuth during treatment.
- After termination of the course of treatment with the preparation in recommended doses, the concentration of active substance in blood plasma does not exceed 3-5.8 µg/l, and intoxication is observed only when its concentration exceeds 100 µg/l.
- When using Novobismol® , stool coloring in dark color due to bismuth sulfide formation is possible. Sometimes a slight darkening of the tongue is observed.
